Study missed primary endpoint of mean time to conversion of SVT to SR over a five-hour period following dosing (p=0.12)
Etripamil showed rapid conversion of SVT to SR during the first 45 minutes (p=0.02), consistent with its known pharmacology
Study demonstrated a positive safety profile showing etripamil was well tolerated in the at-home setting
Small number of placebo patients and prolonged efficacy measurement period confounded results
Company plans to discuss next steps with regulators and continue its full PSVT clinical program, including NODE-301B, NODE-302 and NODE-303
Company to host conference call today at 5:00 p.m. ET
MONTREAL and CHARLOTTE, N.C. , March 23, 2020 /CNW/ -- Milestone Pharmaceuticals Inc. (MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced topline results from its Phase 3, multicenter, randomized, double-blind, placebo-controlled NODE-301 trial of its investigational new drug, etripamil nasal spray, the Company's novel short-acting calcium channel blocker, in patients with paroxysmal supraventricular tachycardia (PSVT).
The NODE-301 trial, which enrolled a total of 431 patients across 65 sites in the U.S. and Canada , is anevent-driven Phase 3 efficacy trial of etripamil for terminating supraventricular tachycardia (SVT) episodes in the at-home setting. Etripamil (70mg) did not achieve its primary endpoint of time to conversion of SVT to sinus rhythm (SR) compared to placebo over the five hour period following study drug administration (median time to conversion of 25 minutes [95% CI: 16, 43] for etripamil vs. 50 minutes [95% CI: 31,101] for placebo, p=0.12). Despite early activity, including the conversion of 61% of etripamil patients vs. 45% of placebo patientsby 45 minutes (p=0.02), a time period consistent with etripamil's known pharmacological activity, results from the latter part of the analysis confounded the statistical analysis of the primary endpoint.
Story continues
The studydemonstrated statistically significant improvements in favor of etripamil over placebo in the important secondary endpoint of patient reported treatment satisfaction, as measured by a treatment satisfaction questionnaire for medication (TSQM-9), including global satisfaction (p=0.0069) and effectiveness scores (p=0.0015), with questions addressing the relief of symptoms commonly associated with an episode of SVT, such as rapid pulse, heart palpitations, anxiety, shortness of breath and dizziness. Additionally, there was a trend in improvement in the percentage of patients seeking rescue medical intervention, including in the emergency department, with etripamil and placebo patients reporting 15% and 27%, respectively (p=0.12).
The safety and tolerability data from the NODE-301 study are supportive of at-home use of etripamil, with adverse events (AE) consistent with those observed in prior trials. The most common AEs observed in patients receiving etripamil were local to the nose, including nasal irritation and congestion, and these events were typically transient in nature and most commonly characterized by the patient as mild in severity. There were no significant differences in incidences of severe adverse events or adverse events of interest, such as atrioventricular nodal blocks or blood pressure-related symptoms, across the etripamil and placebo groups.
NODE-301B, which was designed to collect double-blind data from randomized patients who had not yet experienced an event after the NODE-301 trial reached its target number of adjudicated SVT events, continues. These data will be analyzed separately as a second data set. In addition, open-label safety studies of etripamil in subjects with PSVT, NODE-302 and NODE-303, are ongoing with active recruitment underway. The Company is actively monitoring the potential impact of the COVID-19 pandemic on its ongoing trials and will provide updates on any delayed timelines or cost impacts in the future. The Company expects to request a meeting with regulators to discuss the NODE-301 results and its ongoing studies.
"Efficacy signals across the earlier time points in NODE-301, in both primary and secondary endpoints, correlate directly with our understanding of the drug's known pharmacologic activity. We are also encouraged to see very good safety and tolerability across the broad population enrolled in this study. That said, outcomes after 100 minutes, which were affected by a very small number of placebo patients remaining in the study at that time, suggest that the design and analysis plan used in NODE-301 negatively impacted the study's outcome," said Joseph Oliveto , President and Chief Executive Officer of Milestone Pharmaceuticals. "The overall results of the study reinforce our understanding of the promising profile of etripamil and meaningfully inform us how best to prove its efficacy moving forward."
Mr. Oliveto added: "We will continue to execute as prudently possible on the ongoing NODE studies, including NODE-301B, and look forward to reviewing these data with regulators. The ongoing pandemic highlights the need for, and strengthens our commitment to, home use therapies."
"PSVT places a significant burden on patients and the healthcare system, and a fast-acting therapy to resolve its symptoms when and where episodes occur would have a material impact on both," said Bruce Stambler , MD, FHRS, Piedmont Heart Institute, Atlanta, GA. "NODE-301 is a first-of-its-kind study, and as such encountered a number of challenges relative to studying SVT episodes outside of a controlled electrophysiology laboratory environment. The safety results support at-home use and the multiple efficacy signals show us that, with a confirmatory study, etripamil could fulfill the promise of delivering a fast-acting, patient administered therapy for PSVT."
Conference Call and Webcast
Milestone will host a conference call and webcast to discuss the results of the NODE-301 trial today, March 23, 2020 at 5:00 p.m. ET . To access the live call by phone, dial (800) 529-3311 (domestic) or (470) 495-9164 (international); the conference ID is 6152207. A live audio webcast of the event may also be accessed through the "Investors" section of Milestone's website at http://www.milestonepharma.com. A replay of the webcast will be available for 30 days following the event.
About NODE-301
The NODE-301 trial is a Phase 3, multicenter, randomized, double-blind, placebo-controlled trial of etripamil, the Company's lead investigational product. Etripamil is a novel calcium channel blocker in the form of a nasal spray, intended for the acute treatment of PSVT and other episodic cardiovascular conditions wherever they occur. The study is designed for a population of those PSVT patients who historically experience 20 minutes or longer SVT episodes or episodes requiring termination in the emergency department.Following an in-office test dose of etripamil, 97.5% of patients were randomized (2:1) to receive either 70 mg of etripamil or placebo. Upon onset of PSVT symptoms, patients applied a wireless cardiac monitor to their chest to record heart rhythm, performed a vagal maneuver, and, if symptoms persisted, administered study drug. Of the 198 patient-reported events for which study drug was administered, a total of 156 were confirmed to be SVT events by a central independent adjudication committee and used to assess the study's efficacy endpoints.
The primary endpoint of the NODE-301 study is time to conversion of an SVT episode to sinus rhythm after the administration of study drug, as confirmed by a central independent adjudication committee. Secondary study endpoints include relief of symptoms commonly associated with an episode of SVT such as heart palpitations, chest pain, anxiety, shortness of breath, dizziness, or fainting, and rating of treatment satisfaction questionnaire for medication (TSQM).
About Paroxysmal Supraventricular Tachycardia
Paroxysmal supraventricular tachycardia (PSVT) is a rapid heart rate condition characterized by intermittent episodes of supraventricular tachycardia (SVT) that start and stop suddenly and without warning. Episodes of SVT are often associated with symptoms including palpitations, sweating, chest pressure or pain, shortness of breath, sudden onset of fatigue, lightheadedness or dizziness, fainting, and anxiety. Certain calcium channel blockers have long been approved for the treatment of PSVT as well as other cardiac conditions; however, when calcium channel blockers are used for the termination of SVT episodes, they must be administered intravenously under medical supervision, usually in an emergency department or other acute care setting.
About Etripamil
Etripamil, the Company's lead investigational product, is designed to be a rapid response therapy for episodic cardiovascular conditions. The novel calcium channel blocker is self-administered via a nasal spray which may shift the current treatment paradigm for many patients with PSVT from the emergency department to the at-home setting. Milestone is conducting a comprehensive development program for etripamil, with Phase 3 trials underway in PSVT, and plans to commence a Phase 2 proof-of-concept trial in atrial fibrillation patients with rapid ventricular rate, with subsequent studies expected in other conditions where calcium channel blockers are used.
AboutMilestone Pharmaceuticals
Milestone Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines. Milestone Pharmaceuticals operates in Canada and the United States . For more information, visit http://www.milestonepharma.com and follow the Company on Twitter at @MilestonePharma.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "plan," "anticipate," "estimate," "intend" and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intendedto identify forward-looking statements. These forward-looking statements are based on Milestone's expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Actual results may differ materially from these forward-looking statements. Forward-looking statements contained in this press release include statements regarding (i) the design, progress, timing, scope and results of clinical trials, (ii) potential interactions with regulators, and (iii) the possibility that data will support future development. Important factors that could cause actual results to differ materially from those in the forward-looking statements include, but are not limited to, the risks inherent in biopharmaceutical product development and clinical trials, including the lengthy and uncertain regulatory approval process, uncertainties related to the timing of initiation, enrollment, completion and evaluation of clinical trials, and whether the clinical trials will validate the safety and efficacy of etripamil for PSVT or other indications, among others, as well as risks related to pandemics and public health emergencies, including those related to COVID-19, and risks related the sufficiency of our capital resources and our ability to raise additional capital. These and other risks are set forth in Milestone's filings with the U.S. Securities and Exchange Commission, including in its annual report on Form 10-K for the year ended December 31, 2019 , under the caption "Risk Factors." Except as required by law, Milestone assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.
Contact
David Pitts Argot Partners 212-600-1902 david@argotpartners.com
View original content to download multimedia:http://www.prnewswire.com/news-releases/milestone-pharmaceuticals-announces-topline-results-from-first-of-its-kind-phase-3-node-301-trial-of-etripamil-for-at-home-acute-psvt-treatment-301028371.html
SOURCE Milestone Pharmaceuticals, Inc.
View original content to download multimedia: http://www.newswire.ca/en/releases/archive/March2020/23/c5194.html
- Cardiology and Cardiac Pharmacology [Last Updated On: April 4th, 2018] [Originally Added On: April 4th, 2018]
- EMS Pharmacology: Drugs That Affect the Cardiovascular System ... [Last Updated On: April 8th, 2018] [Originally Added On: April 8th, 2018]
- EMS Pharmacology: Drugs That Affect the Cardiovascular ... [Last Updated On: April 11th, 2018] [Originally Added On: April 11th, 2018]
- Cardiology Conferences - Cardiology and Cardiovascular ... [Last Updated On: June 5th, 2018] [Originally Added On: June 5th, 2018]
- Cardiovascular Pharmacology: Open Access - Open Access ... [Last Updated On: June 21st, 2018] [Originally Added On: June 21st, 2018]
- CV Pharmacology | Welcome to Cardiovascular Pharmacology ... [Last Updated On: July 31st, 2018] [Originally Added On: July 31st, 2018]
- Cardiology Conferences | Cardiac pharmacology 2018 ... [Last Updated On: September 13th, 2018] [Originally Added On: September 13th, 2018]
- Cardiology Conference | Cardiac Pharmacology 2019 ... [Last Updated On: November 18th, 2018] [Originally Added On: November 18th, 2018]
- Cardiovascular Pharmacology Online Course | Lecturio [Last Updated On: November 30th, 2018] [Originally Added On: November 30th, 2018]
- Cardiovascular Pharmacology: Open Access [Last Updated On: December 16th, 2018] [Originally Added On: December 16th, 2018]
- Cardiovascular In vivo Models for Drug Discovery [Last Updated On: December 21st, 2018] [Originally Added On: December 21st, 2018]
- UTHSC College of Medicine: Department of Pharmacology [Last Updated On: February 2nd, 2019] [Originally Added On: February 2nd, 2019]
- Department of Pharmacology - School of Medicine - LSU ... [Last Updated On: April 5th, 2019] [Originally Added On: April 5th, 2019]
- Cardiovascular Pharmacology: Open Access - longdom.org [Last Updated On: April 22nd, 2019] [Originally Added On: April 22nd, 2019]
- ASPET | Cardiovascular Pharmacology [Last Updated On: September 14th, 2019] [Originally Added On: September 14th, 2019]
- Pharmacogenomics Market (PGx) Competitive Research And Precise Outlook 2019 To 2025: Astrazeneca, GeneDX, Illumina, Inc., Laboratory Corporation of... [Last Updated On: September 18th, 2019] [Originally Added On: September 18th, 2019]
- Global and Chinese Microbiome Drugs Market: Industry strategic plan for the period 2019-2024 - Market Report Gazette [Last Updated On: September 18th, 2019] [Originally Added On: September 18th, 2019]
- Pharmacokinetics Market To Increase at Steady Growth Rate - Commerce Gazette [Last Updated On: September 18th, 2019] [Originally Added On: September 18th, 2019]
- Moderna Announces Positive Phase 1 Results for the First Systemic Messenger RNA Therapeutic Encoding a Secreted Protein (mRNA-1944) - BioSpace [Last Updated On: September 18th, 2019] [Originally Added On: September 18th, 2019]
- Janssen to Highlight Depth of Prostate Cancer and Solid Tumor Portfolios with Multiple Data Presentations at ESMO 2019 - Yahoo Finance [Last Updated On: September 18th, 2019] [Originally Added On: September 18th, 2019]
- Cardiac fibrosis study identifies key proteins that translate into heart disease - BSA bureau [Last Updated On: September 18th, 2019] [Originally Added On: September 18th, 2019]
- Nitric Oxide: Worldwide Therapeutics & Markets to 2028 with Profiles on 35 Companies & 18 Collaborations Tabulated - Yahoo Finance [Last Updated On: September 18th, 2019] [Originally Added On: September 18th, 2019]
- Cytokinetics Announces Data From Phase 1 Study of CK-3773274 at the HFSA 23 Annual Scientific Meeting - Yahoo Finance [Last Updated On: September 18th, 2019] [Originally Added On: September 18th, 2019]
- Is it risky to continue with blood thinner drugs after a gastrointestinal bleed? - Medical News Bulletin [Last Updated On: September 18th, 2019] [Originally Added On: September 18th, 2019]
- Women urged to exercise and eat well due to cholesterol after menopause - Sydney Morning Herald [Last Updated On: September 18th, 2019] [Originally Added On: September 18th, 2019]
- Former Executive Director of Preclinical Safety at Novartis, Klaus Peter Hoffmann, MD, PhD, Joins NDA Partners as Expert - Yahoo Finance [Last Updated On: September 18th, 2019] [Originally Added On: September 18th, 2019]
- Yale alumna Dr. Nancy Brown named dean of Yale School of Medicine - Yale News [Last Updated On: September 18th, 2019] [Originally Added On: September 18th, 2019]
- Verve Therapeutics Appoints Cardiologist Andrew Bellinger, M.D., Ph.D., as Chief Scientific Officer - Business Wire [Last Updated On: October 7th, 2019] [Originally Added On: October 7th, 2019]
- G-Protein Coupled Receptors (GPCRs) Market Size And Prediction By Leading Manufacturers According To Its Application And Types Till 2022 - Space... [Last Updated On: October 7th, 2019] [Originally Added On: October 7th, 2019]
- Best supplements for blood pressure: The natural remedy proven to lower your reading - Express [Last Updated On: October 7th, 2019] [Originally Added On: October 7th, 2019]
- Advanced Drug Delivery Systems Market Growth Analysis 2019 to Share Key Aspects of the Industry with the details of Influence Factors Forecast to 2024... [Last Updated On: October 28th, 2019] [Originally Added On: October 28th, 2019]
- The 9 Biggest Technology Trends That Will Transform Medicine And Healthcare In 2020 - Forbes [Last Updated On: November 6th, 2019] [Originally Added On: November 6th, 2019]
- Potential PF Therapy AD-214 to Move into Phase 1 Testing in Humans - Pulmonary Fibrosis News [Last Updated On: November 6th, 2019] [Originally Added On: November 6th, 2019]
- Edited Transcript of CYTK earnings conference call or presentation 31-Oct-19 8:30pm GMT - Yahoo Finance [Last Updated On: November 6th, 2019] [Originally Added On: November 6th, 2019]
- The Montreal Heart Institute celebrates its 500th heart transplant - GlobeNewswire [Last Updated On: November 6th, 2019] [Originally Added On: November 6th, 2019]
- Latest Research Report to uncover key Factors of Global Cardiovascular Repair And Reconstruction Devices Market - Market Research Base [Last Updated On: November 6th, 2019] [Originally Added On: November 6th, 2019]
- Global Cardiovascular Repair And Reconstruction Devices Market: Development History, Current Analysis and Estimated Forecast to 2025 - Market Research... [Last Updated On: November 29th, 2019] [Originally Added On: November 29th, 2019]
- The cardiac safety services market is projected to reach USD 752 million by 2024 from USD 442 million in 2019, at a CAGR of 11.2% - Yahoo Finance [Last Updated On: December 11th, 2019] [Originally Added On: December 11th, 2019]
- Evaluation of the Effect of Fish Oil Alone and in Combination with a P | DMSO - Dove Medical Press [Last Updated On: January 13th, 2020] [Originally Added On: January 13th, 2020]
- Amarin's Multiple Positives And Other News: The Good, Bad, And Ugly Of Biopharma - Seeking Alpha [Last Updated On: January 25th, 2020] [Originally Added On: January 25th, 2020]
- Heres What We Know About CBDs Effects On Varicose Veins - The Fresh Toast [Last Updated On: January 28th, 2020] [Originally Added On: January 28th, 2020]
- Hypertension: This Spice Can Help You Control High Blood Pressure Easily And Effectively - Doctor NDTV [Last Updated On: January 28th, 2020] [Originally Added On: January 28th, 2020]
- Cannabis Manual: Better Together - Weekly Alibi [Last Updated On: January 30th, 2020] [Originally Added On: January 30th, 2020]
- Pharmacology: Cardiovascular Drugs 1 (30 Items) - Nurseslabs [Last Updated On: March 1st, 2020] [Originally Added On: March 1st, 2020]
- A central master driver of psychosocial stress responses in the rat - Science Magazine [Last Updated On: March 9th, 2020] [Originally Added On: March 9th, 2020]
- The Global Cardiac Safety Services Market is expected to grow from USD 419.45 Million in 2018 to USD 865.23 Million by the end of 2025 at a Compound... [Last Updated On: March 29th, 2020] [Originally Added On: March 29th, 2020]
- Fresh Produce In Short Supply? Prioritize This Veggie In Your Diet - mindbodygreen.com [Last Updated On: April 25th, 2020] [Originally Added On: April 25th, 2020]
- COVID-19: What's RNA research got to do with it? - University of Rochester [Last Updated On: May 1st, 2020] [Originally Added On: May 1st, 2020]
- What Happens When You Add Other Drugs To Your LSD Trip? - VICE [Last Updated On: May 1st, 2020] [Originally Added On: May 1st, 2020]
- Toward a Pharmacology of Resolution - Harvard Magazine [Last Updated On: May 1st, 2020] [Originally Added On: May 1st, 2020]
- GLYCOMIMETICS : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q) - marketscreener.com [Last Updated On: May 2nd, 2020] [Originally Added On: May 2nd, 2020]
- This Simple Breathing Advice From A Nobel Prize Winner Can Turn The Tables On Stress During The Coronavirus Lockdown - Forbes [Last Updated On: May 2nd, 2020] [Originally Added On: May 2nd, 2020]
- National Nurses Week 2020: What Experiences Have Shaped Your Nursing Career? - HealthLeaders Media [Last Updated On: May 2nd, 2020] [Originally Added On: May 2nd, 2020]
- Research Paper Stresses Importance of Repurposing Drugs Against COVID-19 - BioSpace [Last Updated On: May 13th, 2020] [Originally Added On: May 13th, 2020]
- Repurposing existing drugs to treat coronavirus will likely be quicker than a vaccine, scientists claim - CNBC [Last Updated On: May 13th, 2020] [Originally Added On: May 13th, 2020]
- Alzheimer's and Cannabis - Greenway - Greenway [Last Updated On: May 18th, 2020] [Originally Added On: May 18th, 2020]
- Moderna Highlights Advances in Platform Science and Innovative Vaccine Research at Third Annual Science Day - Business Wire [Last Updated On: June 2nd, 2020] [Originally Added On: June 2nd, 2020]
- Healthy people shouldn't take daily aspirin to prevent heart disease, review finds - WDJT [Last Updated On: June 6th, 2020] [Originally Added On: June 6th, 2020]
- Study reveals how living close to roadways may impact the brain - Drew Reports News [Last Updated On: June 18th, 2020] [Originally Added On: June 18th, 2020]
- Disruptions in circadian rhythms not only cause sleep disorders, but could also put you at risk of these... - Firstpost [Last Updated On: June 18th, 2020] [Originally Added On: June 18th, 2020]
- NeonMind Files Patent Application for Therapeutic Use of DMT - Yahoo Finance [Last Updated On: June 18th, 2020] [Originally Added On: June 18th, 2020]
- Vitamin D What you need to know about the sunshine vitamin - Medical News Bulletin [Last Updated On: July 9th, 2020] [Originally Added On: July 9th, 2020]
- Idorsia announces positive results in the second Phase 3 study of daridorexant - GlobeNewswire [Last Updated On: July 9th, 2020] [Originally Added On: July 9th, 2020]
- ATAI Life Sciences takes on opioid crisis by acquiring Kures to develop novel therapeutics for opioid abuse - PRNewswire [Last Updated On: July 9th, 2020] [Originally Added On: July 9th, 2020]
- Drug Discovery Outsourcing Market Highly Favorable with new Demand to the Growth Rate by 2027| Thermo Fisher Scientific, Merck KGaA, Albany Molecular... [Last Updated On: August 21st, 2020] [Originally Added On: August 21st, 2020]
- Bringing Peer Review To Early COVID-19 Research, More News - Bio-IT World [Last Updated On: August 21st, 2020] [Originally Added On: August 21st, 2020]
- Cardiac Safety Services Market Research Report by Type of Service, by Type, by End User - Global Forecast to 2025 - Cumulative Impact of COVID-19 -... [Last Updated On: August 21st, 2020] [Originally Added On: August 21st, 2020]
- UCI study finds women with diabetes and high levels of coronary artery calcium at greater risk of death than men - Newswise [Last Updated On: August 21st, 2020] [Originally Added On: August 21st, 2020]
- Globa Advanced Drug Delivery Systems Market 2020 Research, Key Players, Industry Overview, Supply and Consumption Analysis 2024 - Bulletin Line [Last Updated On: September 2nd, 2020] [Originally Added On: September 2nd, 2020]
- Esperion Announces Two Data Presentations of NEXLETOL (bempedoic acid) Tablet at the ESC Congress 2020 - GlobeNewswire [Last Updated On: September 2nd, 2020] [Originally Added On: September 2nd, 2020]
- Women with diabetes and high levels of coronary artery calcium at greater risk of death than men - UCI News [Last Updated On: September 2nd, 2020] [Originally Added On: September 2nd, 2020]
- 15 Clever Ways to Use Leftover Red Wine - Yahoo Lifestyle [Last Updated On: September 2nd, 2020] [Originally Added On: September 2nd, 2020]
- UK Study Leads to Better Understanding of Blood Pressure Regulation, Atherosclerosis - UKNow [Last Updated On: September 2nd, 2020] [Originally Added On: September 2nd, 2020]
- Academic always top of the class for pay and conditions - Extra.ie [Last Updated On: September 15th, 2020] [Originally Added On: September 15th, 2020]
- Cardiac Safety Services Market Size Is Rising Tremendously Due To Increasing Need of Healthcare Services Centralization Till 2025 - TC BizNews [Last Updated On: September 15th, 2020] [Originally Added On: September 15th, 2020]
- 5 Benefits of Berberine, Including Why It's a Healthy Gut All-Star - msnNOW [Last Updated On: September 15th, 2020] [Originally Added On: September 15th, 2020]
- Advanced Drug Delivery Systems Market 2020 Report Covers Key Growth Factors, Global Trends, Opportunities by Regions, Industry Size and Share... [Last Updated On: September 23rd, 2020] [Originally Added On: September 23rd, 2020]
- Janssen Presents Findings from Global, Multi-Center Trial Examining Amivantamab in Combination with Lazertinib in Patients with EGFR-Mutated Non-Small... [Last Updated On: September 23rd, 2020] [Originally Added On: September 23rd, 2020]
- MASSIVE GROWTH OF DRUG DISCOVERY SERVICES MARKET WILL RAISE USD 19.1 BILLION BY 2027, CAGR +13% FROM 2020 TO 2027 WITH TOP KEY PLAYERS LIKE THERMO... [Last Updated On: September 29th, 2020] [Originally Added On: September 29th, 2020]
- The global mice model market size is projected to reach USD 1.9 billion by 2025 from USD 1.4 billion in 2020, at a CAGR of 6.4% - Stockhouse [Last Updated On: September 29th, 2020] [Originally Added On: September 29th, 2020]